Abstract

Background: The SARS-CoV-2 spike protein mediates attachment of the virus to the host cell receptor and fusion between the virus and the cell membrane. The S1 subunit of the spike glycoprotein (S1 protein) contains the angiotensin converting enzyme 2 (ACE2) receptor binding domain. The SARS-CoV-2 variants of concern contain mutations in the S1 subunit. The spike protein is the primary target of neutralizing antibodies generated following infection, and constitutes the viral component of mRNA-based COVID-19 vaccines. Methods: Therefore, in this work we assessed the effect of exposure (24 h) to 10 nM SARS-CoV-2 recombinant S1 protein on physiologically relevant human bronchial (bro) and alveolar (alv) lung mucosa models cultured at air–liquid interface (ALI) (n = 6 per exposure condition). Corresponding sham exposed samples served as a control. The bro-ALI model was developed using primary bronchial epithelial cells and the alv-ALI model using representative type II pneumocytes (NCI-H441). Results: Exposure to S1 protein induced the surface expression of ACE2, toll like receptor (TLR) 2, and TLR4 in both bro-ALI and alv-ALI models. Transcript expression analysis identified 117 (bro-ALI) and 97 (alv-ALI) differentially regulated genes (p ≤ 0.01). Pathway analysis revealed enrichment of canonical pathways such as interferon (IFN) signaling, influenza, coronavirus, and anti-viral response in the bro-ALI. Secreted levels of interleukin (IL) 4 and IL12 were significantly (p < 0.05) increased, whereas IL6 decreased in the bro-ALI. In the case of alv-ALI, enriched terms involving p53, APRIL (a proliferation-inducing ligand) tight junction, integrin kinase, and IL1 signaling were identified. These terms are associated with lung fibrosis. Further, significantly (p < 0.05) increased levels of secreted pro-inflammatory cytokines IFNγ, IL1ꞵ, IL2, IL4, IL6, IL8, IL10, IL13, and tumor necrosis factor alpha were detected in alv-ALI, whereas IL12 was decreased. Altered levels of these cytokines are also associated with lung fibrotic response. Conclusions: In conclusion, we observed a typical anti-viral response in the bronchial model and a pro-fibrotic response in the alveolar model. The bro-ALI and alv-ALI models may serve as an easy and robust platform for assessing the pathogenicity of SARS-CoV-2 variants of concern at different lung regions.

Highlights

  • IntroductionThe SARS-CoV-2 spike protein is the primary target of neutralizing antibodies generated following infection

  • The spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), responsible for causing the coronavirus disease-2019 (COVID-19), mediates attachment of the virus to host cell-surface receptor and fusion between virus and cell membrane [1].The spike protein consists of two subunits: S1 (containing the angiotensin converting enzyme 2 (ACE2) receptor-binding domain) and S2 [2].The SARS-CoV-2 spike protein is the primary target of neutralizing antibodies generated following infection

  • We investigated the effects of SARS-CoV-2 spike glycoprotein 1 on two different lung regions—bronchial and alveolar—using physiologically relevant human lung mucosal models developed at air–liquid interface

Read more

Summary

Introduction

The SARS-CoV-2 spike protein is the primary target of neutralizing antibodies generated following infection It constitutes the viral component of both mRNA and adenovirusbased vaccines for COVID-19. Examination of lungs of deceased COVID-19 patients compared to uninfected age-matched control subjects revealed greater number of ACE2-positive alveolar epithelial cells [8,9]. In this context, the plausible role of using bronchoalveolar lavage fluid among patients with a negative COVID-19 from nasopharyngeal swab to establish a different diagnosis may be considered by performing additional molecular analysis [10]. Results: Exposure to S1 protein induced the surface expression of ACE2, toll like receptor (TLR) 2, and TLR4 in both bro-ALI and alv-ALI models

Objectives
Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call